key: cord-0950103-6rvn27mz
authors: Dorjee, Kunchok; Kim, Hyunju; Bonomo, Elizabeth; Dolma, Rinchen
title: Prevalence and predictors of death and severe disease in patients hospitalized due to COVID-19: A comprehensive systematic review and meta-analysis of 77 studies and 38,000 patients
date: 2020-12-07
journal: PLoS One
DOI: 10.1371/journal.pone.0243191
sha: e1b962a2f386dd771cf582774f6d0abed2d84c11
doc_id: 950103
cord_uid: 6rvn27mz

INTRODUCTION: Progression of COVID-19 to severe disease and death is insufficiently understood. OBJECTIVE: Summarize the prevalence of risk factors and adverse outcomes and determine their associations in COVID-19 patients who were hospitalized. METHODS: We searched Medline, Embase and Web of Science for case-series and observational studies of hospitalized COVID-19 patients through August 31, 2020. Data were analyzed by fixed-effects meta-analysis using Shore’s adjusted confidence intervals to address heterogeneity. RESULTS: Seventy-seven studies comprising 38906 hospitalized patients met inclusion criteria; 21468 from the US-Europe and 9740 from China. Overall prevalence of death [% (95% CI)] from COVID-19 was 20% (18–23%); 23% (19–27%) in the US and Europe and 11% (7–16%) for China. Of those that died, 85% were aged≥60 years, 66% were males, and 66%, 44%, 39%, 37%, and 27% had hypertension, smoking history, diabetes, heart disease, and chronic kidney disease (CKD), respectively. The case fatality risk [%(95% CI)] were 52% (46–60) for heart disease, 51% (43–59) for COPD, 48% (37–63) for chronic kidney disease (CKD), 39% for chronic liver disease (CLD), 28% (23–36%) for hypertension, and 24% (17–33%) for diabetes. Summary relative risk (sRR) of death were higher for age≥60 years [sRR = 3.6; 95% CI: 3.0–4.4], males [1.3; 1.2–1.4], smoking history [1.3; 1.1–1.6], COPD [1.7; 1.4–2.0], hypertension [1.8; 1.6–2.0], diabetes [1.5; 1.4–1.7], heart disease [2.1; 1.8–2.4], CKD [2.5; 2.1–3.0]. The prevalence of hypertension (55%), diabetes (33%), smoking history (23%) and heart disease (17%) among the COVID-19 hospitalized patients in the US were substantially higher than that of the general US population, suggesting increased susceptibility to infection or disease progression for the individuals with comorbidities. CONCLUSIONS: Public health screening for COVID-19 can be prioritized based on risk-groups. Appropriately addressing the modifiable risk factors such as smoking, hypertension, and diabetes could reduce morbidity and mortality due to COVID-19; public messaging can be accordingly adapted.

Coronavirus disease-19 caused by severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) that first emerged in Wuhan, China in late December 2019 has spread with such rapidity and efficiency that in less than 10 months, it has caused more than 36 million cases and million deaths globally [1] . Driven by an urgency to solve the crisis, studies are being published at an unprecedented pace. However, across the publications, prevalence of death, severe disease and their association with epidemiological risk factors have greatly varied [2, 3] , with studies showing conflicting results for association of key risk factors such as sex [4] [5] [6] [7] [8] , smoking [9] [10] [11] [12] , hypertension [4, 7, 8, 13, 14] and diabetes [4, 7, 8, 13, 14] with COVID-19 disease severity and death. Whether or how cardiovascular risk factors, especially prior hypertension, diabetes and heart disease are associated with acquisition of SARS-CoV-2 and progression to severe disease or death is not understood well [15] [16] [17] [18] . Meta-analyses conducted so far on prevalence of epidemiological risk factors and association with disease progression were mostly based on studies from China [9, 11, [18] [19] [20] and many of the analyses on prevalence estimates included studies focused on critically ill patients [9, 19] , which can overestimate the prevalence and affect generalizability of results. To our knowledge, none of the analyses were restricted to hospitalized COVID-19 patients. Restricting our analysis to hospitalized patients provides an efficient sampling frame to investigate disease progression in relation to risk factors. Therefore, we undertook a comprehensive systematic review and meta-analysis to investigate the association between key epidemiological factors-age, gender, smoking, hypertension, diabetes, heart disease, chronic obstructive pulmonary disease (COPD), chronic kidney disease (CKD) and chronic liver disease (CLD)-and progression to death and severe disease in patients hospitalized due to COVID-19. We additionally compared the 1) the prevalence of risk factors and death in the US-Europe with that of China; 2) the prevalence of co-morbidities at baseline with the general population prevalence, and 3) prevalence of cardiovascular disease, COPD and CKD at baseline with corresponding organ injuries (acute cardiac injury, acute lung injury, and acute kidney injury) during hospital admission.

We searched Medline, Embase, Web of Science and the WHO COVID-19 database to identify studies published through August 31, 2020 that investigated the risk of severe disease or death in hospitalized patients with confirmed COVID-19 disease. We used search terms, 'coronavirus disease 19', 'COVID-19', 'severe acute respiratory syndrome coronavirus 2' and 'SARS-CoV-2' for COVID-19 and the string ((characteristics) OR (risk factors) OR (epidemiology) OR (prevalence) OR (intensive care) OR (ventilator) OR (mechanical ventilator) OR (mortality) OR (survivor � ) OR (smoking) OR (smoker � )) AND ((COVID-19) OR (COVID) OR (coronavirus)) for studies published between December 15, 2019 and August 31, 2020. We started the search on March 18, 2020 with biweekly search thereafter and final search on August 31, 2020. We included case series and observational studies that described the prevalence of death or severe disease in adult population stratified by risk factors: age, sex, hypertension, diabetes, heart disease, COPD, CKD and CLD. We excluded studies that included nonconsecutive patients or exclusively focused on pregnant women, children, and elderly patients. We excluded studies that exclusively studied critically ill patients from calculation of prevalence of death but included them for calculating the association of risk factors with death. Screening of abstracts and full-text reviews were conducted using Covidence (Melbourne, Australia).

Primary outcomes were prevalence of death and association of risk factors with death. We extracted data on death as recorded in the publications. We measured prevalence of severe disease and association with risk factors as secondary outcomes. We defined outcome as severe disease for any of 1) the study classified COVID-19 disease as severe or critical, 2) intensive care unit (ICU) admission, 3) acute respiratory distress syndrome, or 4) mechanical ventilation. Severe disease was defined by studies as respiratory rate�30 per minute, oxygen saturation�93%, and PaO 2 /FiO 2 <300 and/or lung infiltrates>50% within 24-48 hours [3] . Critical illness was defined as respiratory failure, shock and/or multiple organ dysfunction or failure [3] . Heart disease as a pre-existing condition was broadly defined by most studies as 'cardiovascular disease' (CVD). Additional outcomes were acute cardiac and kidney injury in the hospitalized patients that were defined as such by the studies.

We calculated and reported summary estimates from fixed-effects models [21] . We assessed heterogeneity across studies using Cochran's Q-test (χ 2 p value <0.10) [22] and I 2 statistics (I 2 >30%) [23] . In the presence of heterogeneity, we adjusted the confidence intervals for between-study heterogeneity using the method described by Shore et al. [24] . We presented the results from random effects meta-analysis as well. The meta-analysis was performed in Microsoft 1 Excel 2020 (Microsoft Corporation, Redmond, WA). We analyzed publication bias using funnel plots and Egger's tests. Quality of each study was assessed using the Newcastle-Ottawa assessment scales using the PRISMA guidelines. We calculated the following as a part of our analyses: 1) prevalence of severe disease or death, 2) prevalence of risk factors, and 3) relative risk for the association of age, sex, and comorbidities with outcome. When not reported or when unadjusted odds ratio was presented, we calculated the relative risk (95% CI) using the frequencies provided. Adjusted estimates were used where available. Case fatality risk (and case severity risk) for a specific risk factor was calculated as number of deaths (or severe disease) in patients with a risk factor out of all patients possessing the risk factor.

Initial search yielded 30133 citations. Articles were then screened (Fig 1) . We identified 410 articles for full text review, of which 77 studies met inclusion criteria (Table 1) [4-8, 13, 14, 25-94] . The studies were conducted in: China (n = 35), USA (n = 18), Europe (n = 10), rest of Asia (n = 5) and Africa (n = 1). Two studies were prospective, five cross-sectional, and remaining retrospective in nature. 

We calculated an overall prevalence of death of 20% [95% CI: 18-23%; I 2 = 96%; n = 60], ranging from 1% to 38% across the studies, and of severe disease of 28% [95% CI: 24-33%; I 2 = 98%; n = 60] for all patients hospitalized due to COVID-19 (Tables 2 and 3 ). Data on 

prevalence of death, severe disease, and risk factors (S1 Table) , and association of the risk factors with death (S2 Table) and severe disease (S3 Table) for the individual studies are presented in the supplemental tables.

Predictors of death and severe disease (Tables 2 and 3 (Fig 2A) .

Diabetes. (Fig 3B) .

Chronic kidney disease. 86 ; I 2 = 85%; n = 27] compared to non-CKD patients (Fig 3C) .

Chronic liver disease. The prevalence of CLD was 2% [95% CI: 2-3%; I 2 = 72%; n = 31] with a CFR of 39% [95% CI: 31-50%; I 2 = 0%; n = 8] and CSR of 43% [95% CI: 32-57%; I 2 = 5%; n = 12] in CLD patients. CLD was present in 6% [95% CI: 4-8%; I 2 = 0%; n = 8] of the (Fig 3D) .

To understand how pre-existing health conditions may be correlated with the risk of specific organ injury, we calculated the prevalence of acute injury to lung, heart and kidney for studies that reported prevalence of both the pre-existing condition(s) and corresponding organ injury (Fig 4A) . Pooled across 12 studies [14, 25, 32, 45, 48, 49, 52, 54, 60, 62, 79] 

Upon sub-group analysis, we noted significantly higher prevalence of death and risk factors among COVID-19 patients in the US and Europe than in China (Fig 4B) . 

In order to gain some understanding of whether patients with comorbidities are at higher risk of COVID-19 infection or hospitalization, we compared the prevalence of comorbidities between COVID-19 patients hospitalized in the US and the prevalence of comorbidities in the general US population. We observed that the prevalence of hypertension (55%), diabetes (33%), CVD (17%), and smoking history (23%) were substantially higher in the COVID-19 patients than in the general US population (Fig 4C) . For the Chinese population, the overall prevalence of hypertension (23%) and diabetes (12%) in the COVID-19 patients were similar to that of the general Chinese population. However, the prevalence of smoking history (11%), COPD (4%), CKD (2%), and heart disease (16%) in the COVID-19 patients hospitalized in China were unexpectedly lower as compared to their corresponding prevalence in the general Chinese population (Fig 4D) .

The positive associations of age�65 years, male sex, smoking history, COPD, hypertension and diabetes with the risk of death in the COVID-19 patients were relatively homogenous (I 2 <70%). However, we carried out sensitivity analyses to assess the effects of outliers. For the risk of death for hypertension and smoking history, we removed the study by Yao et al. [86] which showed significantly higher risk compared to other studies; the results for both hypertension [sRR = 1.74; 95% CI: 1.58-1.94] and smoking [sRR:1.24; 95% CI: 1.08-1.42] remained significant. Guan et al. [13] had published a second study with additional patients and reported adjusted estimates for COPD, diabetes and hypertension. We used the adjusted risk estimates for the analyses. For the risk of death with other risk factors (CVD, CKD, and CLD) for Guan et al. [45] , we conducted sensitivity analyses by using the counts only from the original study. 

We observed asymmetry in the funnel plot for studies that reported prevalence of death in COVID-19 patients (Egger's test p = 0.001) (S1 Fig). On further analysis, the plot remained asymmetrical when restricted to studies from China (Egger's p = 0.003) but was symmetrical for studies from US-Europe (Egger's p = 0.160). We observed symmetrical funnel plots with no bias for pooled prevalence severe disease (Egger's p = 0.128). On average, prospective or retrospective studies scored a score of 6 out of 9 and cross-sectional studies scored 6 out of 10. Many studies did not get a full score because they did not adjust for confounders (age, sex, or other risk factors) or patients remained hospitalized even after the follow-up ended, suggesting inadequate follow-up period (S4 Table) .

We carried out a comprehensive systematic review and meta-analysis of 77 studies that included 38906 hospitalized patients to investigate the prevalence and risk factors for death and severe disease in COVID-19 patients. We calculated an overall prevalence of death of 20% and severe disease of 28%. Nearly 50% of the patients admitted to hospitals due to COVID-19 were �60 years of age and 59% were males. We observed high prevalence of hypertension and diabetes of 50% and 28%, respectively, for the patients. The risk factors were more prevalent in patients who died and were distributed as: age �60 years: 85%; males: 66%; hypertension: 66%; diabetes: 39%; heart disease: 37%; CKD: 27%; smoking history: 44%; COPD: 12%, and CLD: 9%. In comparison with the overall prevalence of death of 20% for all COVID-19 hospitalized patients, the CFR was higher for male patients (26%) and for patients having the following risk factors: age�60 years (35%), heart disease (52%), COPD (51%), CKD (48%), CLD (39%), hypertension (28%), diabetes (24%), and smoking history (27%). The elevation in the risk of death was statistically significant for age �60 (sRR = 3.6; 95% CI: 3.0-4.4), male sex 1.3 (95% CI: 1.2-1.4), smoking history (sRR = 1.3; 95% CI: 1.1-1.6), COPD (sRR = 1.7; 95% CI: 1.4-2.0), heart disease (sRR = 2.1; 95% CI: 1.8-2.4), CKD (sRR = 2.5; 95% CI: 2.1-3.0), hypertension (sRR = 1.8; 95% CI: 1.7-2.1), and diabetes (sRR = 1.5; 95% CI: 1.4-1.7). All of the risk factors we analyzed were positively associated with progression to severe disease as well. The results suggest that older age, male sex and the co-morbidities increase the risk of progression to severe disease and death in COVID-19 patients. We observed significant difference in the prevalence of death between US-Europe (23%) and China (11%). This lower risk of death from COVID-19 for the hospitalized patients in China may be explained by the lower median age as well as lower prevalence of co-morbidities for COVID-19 patients in China. However, this >200% lower prevalence of death in China is incommensurate with our finding of a higher prevalence of severe disease observed for patients in China (39%) as compared to patients in the US-Europe (20%). Notably, we observed asymmetry in the funnel plot and a statistically significant tests for publication bias or small study effects for the prevalence of death for studies from China that could suggest selective outcome reporting. As such, while the lower median age and prevalence of co-morbidities for COVID-19 patients in China may explain the lower prevalence of death, it is also possible that a selective under-reporting of death had occurred for studies from China. The death toll in China was initially under-reported and later updated on April 17, 2020 [95] .

Whether or not cigarette smoking has been associated with SARS-CoV-2 acquisition or progression to severe disease has been strongly debated with studies showing both positive, null, and inverse association between smoking and COVID-19 [10, 11, [96] [97] [98] . We found that patients with any history of smoking have both a higher risk of death (RR: 1.28; 95% CI: 1.06-1.55) and severe disease (1.29; 95% CI: 1.18-1.42). The case fatality risk for those with smoking history (27%) was also higher than the overall CFR of 20%. Whereas a higher COVID-19 mortality and morbidity among smokers may be due its causal association with COPD and CVD, Cai et al. [99] has also observed upregulation of pulmonary Angiotensin Converting Enzyme 2 (ACE2) gene expression and hence, pulmonary ACE2 receptors in smokers suggesting a direct effect of smoking on COVID-19 susceptibility and disease progression. ACE2 receptors are used by SARS-CoV-2 to translocate intracellularly [15, [100] [101] [102] [103] [104] .

Our results of higher risk of death and severe disease associated with hypertension, diabetes and CVD in COVID-19 patients concurred with most studies conducted to date including studies that specifically investigated these associations [14, 65, 105, 106] . However, it is unclear if cardiovascular risk factors including smoking, hypertension, diabetes, heart disease and CKD increases the susceptibility toward SARS-CoV-2 infection in the population [15, 100, 101, 107] . On one hand, angiotensin-converting enzyme 2 (ACE2)-by blocking the renin angiotensin aldosterone system (RAAS) and decreasing or countering the vasoconstrictive, proinflammatory and profibrotic properties of angiotensin-II through catalysis of angiotensin-II to angiotensin-(1-7)-have been shown to exert cardiovascular protective effect and prevent acute lung injury from SARS-CoV-2 [15, 100, 101] . However, on the other hand, a possible greater expression of ACE2, the functional receptor mediating cellular entry of SARS-CoV-2 in humans, in patients with cardiovascular disease and other comorbidities can lead to increased susceptibility towards infection with SARS-CoV-2 [108, 109] . In this context, it would be reasonable to posit that a substantially higher prevalence of cardiovascular comorbidities in the hospitalized patients compared to the prevalence in the general population may suggest elevated risk of acquisition of SARS-CoV-2 for patients with cardiovascular risk factors. To this end, we found that the prevalence of smoking history (23%), hypertension (55%), diabetes (33%) and heart disease (17%) in the hospitalized COVID-19 patients in the US were substantially higher than the corresponding prevalence of smoking (14%) [110] , hypertension (29%) [111] , diabetes (13%) [112] and heart disease (9%) [113] in the general US population that could suggest an association between these comorbidities and risk of SARS-CoV-2 infection or disease progression. However, we note that if the prevalence of these comorbidities in the asymptomatic individuals with COVID-19 in the general population is similar to that of their prevalence in the non-COVID-19 general population, then this difference-the higher prevalence of comorbidities in the hospitalized patients compared to the general populationcould simply imply a higher risk of symptomatic infection or hospitalization for individuals having SARS-CoV-2 infection. The prevalence of other risk factors i.e. COPD (9%) and CKD (15%) in the COVID-19 patients in the US was similar to the overall prevalence of COPD (7%) [114] and CKD (15%) [115] in the country. Generally, we noted a lower prevalence of comorbidities for patients in China. The prevalence of hypertension (23%) and diabetes (12%) in the hospitalized patients in China, which were lower than that of the US, approximate the respective prevalence of hypertension (23%) [116] and diabetes (15%) [117] in the general population of China. A previous meta-analysis also noted this observation [19] . Surprisingly, the prevalence of smoking (11%) in the COVID-19 patients hospitalized in China are inexplicably lower than the corresponding prevalence of smoking (23%) among COVID-19 patients in the US despite a higher prevalence of smoking (47% in Chinese males) [118] in the general Chinese population is significantly higher than that of the US. The prevalence of CVD (16%), COPD (4%) and CKD (2%) among COVID-19 patients in China are substantially lower than the corresponding prevalence of CVD (21%) [119] , COPD (14%) [120] , and CKD (11%) [121] in the general Chinese population. Given these discrepancies, we are unsure whether the lower prevalence of comorbidities noted for the COVID-19 patients in China are representative of the true prevalence. There was a great sense of urgency and a race to publish data in the early phase of the outbreak. As such, there exists the possibility of substantial under-recording of data on covariables. Had there been under-reporting, the implication would be a higher true prevalence estimate. We do not see reason for any systematic difference in reporting of risk factors based on outcome, or vice-versa, and hence, our summary relative risk estimates for association of risk factors with death or severe disease should not have been affected.

We assessed if patients with specific co-morbidities at baseline had higher risk of specific organ injury from SARS-CoV-2 during hospitalization. While the available data did not allow direct assessment of this relation, we compared the prevalence of comorbidities with the prevalence of corresponding organ system injury for studies that reported both baseline comorbidity and corresponding organ injury. We observed that the risk of acute lung injury/ARDS (48%), ACI (21%), and AKI (27%) were substantially higher than the baseline prevalence of COPD (6%), heart disease (11%) and CKD (14%), respectively. The higher prevalence of acute organ injury than the prevalence of baseline comorbidity simply indicates that ARDS, ACI and AKI were also occurring in patients who did not have a corresponding comorbidity at baseline in addition to people having the comorbidities.

Most studies reported only frequencies of risk factors and did not present adjusted measures for disease severity or death. Given this limitation, the risk ratio we calculated from the frequencies are largely unadjusted estimates. Future studies could additionally present, at the least, age-and sex-adjusted measures for association of risk of comorbidities with death or severe disease. Many studies reported odds ratio for the measure of association between preexisting conditions and risk of severe disease or death. Odds ratio poorly approximates risk ratio when the disease prevalence is high at baseline. For example, Zhou et al. [14] calculated an odds ratio of 5.4 (95% CI: 0.96-30.4) for risk of death from COPD in COVID-19 patients whereas the risk ratio we calculated from the frequencies presented is RR = 2.47 (95% CI: 1. 34-4.55) . Prevalence of severe disease or death in COVID-19 patients was high in several studies. Similarly, several meta-analyses calculated odds ratios instead of risk ratios to summarize the risk of disease severity or death in association with risk factors such as smoking, diabetes, hypertension and cardiovascular disease [10, 11, 18] , often to be interpreted by media and even by researchers as a measure of relative risk. Lack of rigor in research design, analysis and interpretation could generate inconsistent and ungeneralizable results across studies leading to controversy and confusion around serious public health issues such as that existing for association (or not) of smoking with COVID-19 disease acquisition, severity or death. As publications evolve at a pace that could be overwhelming for researchers and practitioners, we attempted to present a meaningful summary and inference for association of risk factors with death or severe disease from literatures published globally. Additionally, we provide an epidemiological framework for the risk of infection by SARS-CoV-2 based on presence of cardiovascular risk factors. This analysis can inform public health measures for COVID-19 screening and prevention, risk stratification and management of patients in clinical practice, analysis and presentation strategies for research data and inspire etiological investigations.

Epidemiological risk factors for progression of COVID-19 to severe disease and death and for acquisition of SARS-CoV-2, the causal agent for COVID-19, based on presence of pre-existing conditions have been insufficiently understood. Meta-analysis of 77 studies including 39023 COVID-19 patients hospitalized globally revealed case fatality risk of 52% for those having heart disease, 51% for COPD, 48% for CKD, 39% for CLD, 28% for hypertension, 27% for smoking history, 24% for diabetes, 35% for age�60 years, and 26% for males. Of all the patients who died, an overwhelming majority (85%) were in people aged�60 years. Also, of the people who died, 66% were males, 66% had hypertension, 44% had history of smoking, 39% had diabetes, 37% had CVD, 27% had CKD, and 6% had CLD. All of the above risk factors were significantly associated with death and severe disease in the patients hospitalized for COVID-19. The prevalence of ARDS was 48%, ACI 21%, and AKI 28% in the hospitalized patients. A higher prevalence of hypertension, diabetes, smoking and heart disease in the COVID-19 inpatients as compared to that of the general population could imply a higher risk of SARS-CoV-2 infection or disease progression for patients having these risk factors. These findings could inform public health strategies for targeted screening and appropriate control of modifiable risk factors such as smoking, hypertension, and diabetes to reduce morbidity and mortality. Finally, based on the published literature, there were vast differences in the prevalence of death and risk factors for the populations in China and in US-Europe that should be further investigated. Table. Newcastle-Ottawa quality assessment (modified) for studies # . # Award of Points: Selection: points were awarded based on representativeness of the exposed group and unexposed group (2 points), ascertainment of exposures (1 point), and demonstration that outcome of interest was not present at the start of the study (1 point). Comparability (2 points): points were awarded based on whether the analyses were adjusted for age, sex, and other risk factors (2 points for adjustment to age and sex). Outcome (3points): points were awarded based on ascertainment of outcome through record linkage or independent blind assessment (1 points); duration of follow-up (1 point) (hospitalization till discharge); and adequacy of follow up for study population (complete follow up for the patients (vs whether patients were currently under treatment at the time of study report) (1 point), or if the patients currently under admission are excluded from outcome assessment (1 point). 

Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019-COVID-NET, 14 States

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention

Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study

Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study

Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan

Severe obesity, increasing age and male sex are independently associated with worse in-hospital outcomes, and higher in-hospital mortality

Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease

Severity and Mortality associated with COPD and Smoking in patients with COVID-19: A Rapid Systematic Review and Meta-Analysis

Active smoking is not associated with severity of coronavirus disease 2019 (COVID-19)

Smoking Is Associated With COVID-19 Progression: A Meta-analysis

Current smoking is not associated with COVID-19

Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

COVID-19 and the Heart

Hypertension and COVID-19

COVID-19 and the cardiovascular system

Impact of cardiovascular disease and cardiac injury on in-hospital mortality in patients with COVID-19: a systematic review and meta-analysis

Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis

Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis

Meta-analysis in clinical trials

The Combination of Estimates From Different Experiments

Quantifying heterogeneity in a meta-analysis

Ethylene oxide: an assessment of the epidemiological evidence on carcinogenicity

Clinical features, laboratory characteristics, and outcomes of patients hospitalized with coronavirus disease 2019 (COVID-19): Early report from the United States

Characterization and clinical course of 1000 patients with coronavirus disease 2019 in New York: retrospective case series

COVID-19: a retrospective cohort study with focus on the over-80s and hospital-onset disease

Clinical characteristics of Coronavirus Disease

Clinical and immunological features of severe and moderate coronavirus disease 2019

Clinical progression of patients with COVID-19 in Shanghai

Clinical characteristics of 145 patients with corona virus disease 2019 (COVID-19

Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study

Predictors of Mortality in Adults Admitted with COVID-19: Retrospective Cohort Study from New York City

Early predictors of clinical outcomes of COVID-19 out

Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 in Wuhan, China: a retrospective study

Risk factors for mortality in patients with Coronavirus Disease 2019 (COVID-19) in Bolivia: An analysis of the first 107 confirmed cases

COVID-19 with Different Severities: A Multicenter Study of Clinical Features

Characteristics and Outcomes of Coronavirus Disease Patients under Nonsurge Conditions

A clinical risk score to identify patients with COVID-19 at high risk of critical care admission or death: An observational cohort study

Patient Trajectories Among Persons Hospitalized for COVID-19: A Cohort Study

30-day mortality in patients hospitalized with COVID-19 during the first wave of the Italian epidemic: A prospective cohort study

Characteristics and Clinical Outcomes of Adult Patients Hospitalized with COVID-19-Georgia

Clinical Characteristics of Covid-19 in New York City

Characteristics, predictors and outcomes among 99 patients hospitalised with COVID-19 in a tertiary care centre in Switzerland: an observational analysis

Clinical Characteristics of Coronavirus Disease 2019 in China

The effect of frailty on survival in patients with COVID-19 (COPE): a multicentre, European, observational cohort study

Race/Ethnicity, Underlying Medical Conditions, Homelessness, and Hospitalization Status of Adult Patients with COVID-19 at an Urban Safety-Net Medical Center

Risk Factors Associated with Clinical Outcomes in 323 COVID-19 Hospitalized Patients in Wuhan, China. Clin Infect Dis

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Factors Associated With Intubation and Prolonged Intubation in Hospitalized Patients With COVID-19

Age and Multimorbidity Predict Death Among COVID-19 Patients: Results of the SARS-RAS Study of the Italian Society of Hypertension

Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy

Prognostic Factors for Severe Coronavirus Disease 2019 in Daegu

Clinical and laboratory findings from patients with COVID-19 pneumonia in Babol North of Iran: a retrospective cohort study

Association of Obesity with Disease Severity Among Patients with Coronavirus Disease

Clinical characteristics and 28-day mortality of medical patients admitted with COVID-19 to a central London teaching hospital

Clinical characteristics and outcomes of the first 63 adult patients hospitalized with COVID-19: An experience from Oman

Characteristics and early outcomes of patients hospitalised for COVID-19 in North Zealand, Denmark

Clinical characteristics and risk factors of patients with severe COVID-19 in Jiangsu province, China: a retrospective multicentre cohort study

Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease

Epidemiological characteristics of coronavirus disease 2019 (COVID-19) patients in IRAN: A single center study

Clinical characteristics and short-term outcomes of patients with coronavirus disease 2019: a retrospective single-center experience of a designated hospital in Poland

Coronavirus disease 19 in minority populations of Newark, New Jersey

Characteristics, comorbidities, 30-day outcome and in-hospital mortality of patients hospitalised with COVID-19 in a Swiss area-a retrospective cohort study

Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the

Sociodemographic, clinical and laboratory factors on admission associated with COVID-19 mortality in hospitalized patients: A retrospective observational study

Clinical, radiological and therapeutic characteristics of patients with COVID-19 in Saudi Arabia

Epidemiological and clinical features of 2019 novel coronavirus diseases (COVID-19) in the South of Iran

Early experience with COVID-19 patients at academic hospital in Southwestern United States

Host susceptibility to severe COVID-19 and establishment of a host risk score: findings of 487 cases outside Wuhan

Clinical Characteristics and Morbidity Associated With Coronavirus Disease 2019 in a Series of Patients in Metropolitan Detroit

Clinical features of patients with coronavirus disease 2019 from a designated hospital in Beijing

An epidemiological study of laboratory confirmed COVID-19 cases admitted in a tertiary care hospital of Pune, Maharashtra

Preliminary Estimates of the Prevalence of Selected Underlying Health Conditions Among Patients with Coronavirus Disease 2019-United States

Characteristics of COVID-19 infection in Beijing

Clinical features of 95 sequential hospitalised patients with novel coronavirus 2019 disease (COVID-19), the first UK cohort

Risk factors for severe illness in hospitalized Covid-19 patients at a regional hospital

Clinical features and treatment of COVID-19 patients in northeast Chongqing

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan

Epidemiological and clinical features of 125 Hospitalized Patients with COVID-19 in

Clinical Features of 69 Cases With Coronavirus Disease

Clinical characteristics of 276 hospitalized patients with coronavirus disease

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

A retrospective study of risk factors for severe acute respiratory syndrome coronavirus 2 infections in hospitalized adult patients

Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore

Association Between Clinical Manifestations and Prognosis in Patients with COVID-19

Epidemiological and clinical characteristics of 333 confirmed cases with coronavirus disease

Retrospective analysis of clinical characteristics of 405 patients with COVID-19

Analysis of clinical characteristics and laboratory findings of 95 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a retrospective analysis. Respiratory Research

Risk factors for disease severity, unimprovement, and mortality in COVID-19 patients in Wuhan, China

Clinical characteristics of 140 patients infected by SARS-CoV-2 in Wuhan

Clinical characteristics of patients with 2019 coronavirus disease in a non-Wuhan area of Hubei Province, China: a retrospective study

Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province

Epidemiological and Clinical Characteristics Analysis of COVID-19 in the Surrounding Areas of Wuhan, Hubei Province in 2020

China Raises Coronavirus Death Toll by 50% in Wuhan. The New York Times

National Smoking Rates Correlate Inversely with COVID-19 Mortality. 2020

Factors associated with COVID-19-related death using OpenSAFELY

The impact of COPD and smoking history on the severity of COVID-19: A systemic review and meta-analysis

Tobacco Smoking Increases the Lung Gene Expression of ACE2, the Receptor of SARS-CoV-2

COVID-19 and Cardiovascular Disease

COVID-19, ACE2, and the cardiovascular consequences

Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus

Clinical Features of COVID-19 in Patients With Essential Hypertension and the Impacts of Renin-angiotensin-aldosterone System Inhibitors on the Prognosis of COVID-19 Patients

Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes

Hypertension, the renin-angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19

Distribution of ACE2, CD147, CD26, and other SARS-CoV-2 associated molecules in tissues and immune cells in health and in asthma, COPD, obesity, hypertension, and COVID-19 risk factors

ACE2 Expression Is Increased in the Lungs of Patients With Comorbidities Associated With Severe COVID-19

Tobacco Product Use and Cessation Indicators Among Adults -United States

Heart Disease and Stroke Statistics-2019 Update: A Report From the

Prevalence and Treatment of Chronic Obstructive Pulmonary Disease (COPD) in the United States

United States Centers for Disease Control and Prevention. Chronic Kidney Disease in the United States

Status of Hypertension in China: Results From the China Hypertension Survey

Diabetes in China: Epidemiology and Genetic Risk Factors and Their Clinical Utility in Personalized Medication

Trends in smoking prevalence and implication for chronic diseases in China: serial national cross-sectional surveys from

China cardiovascular diseases report 2018: an updated summary

Chronic obstructive pulmonary disease in China: a nationwide prevalence study

Prevalence of chronic kidney disease in China: a cross-sectional survey